Spruce Biosciences Inc
(NAS:SPRB)
$
0.4054
0.0099 (2.5%)
Market Cap: 16.34 Mil
Enterprise Value: -40.49 Mil
PE Ratio: 0
PB Ratio: 0.32
GF Score: 32/100 Spruce Biosciences Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2022 / 02:00PM GMT
Release Date Price:
$1.47
(+9.70%)
Yinglu Zhang
RBC Capital Markets - Analyst
Welcome to the 2022 RBC Global Healthcare Conference. My name is Yinglu Zhang, one of the Biotech Equity Research Analysts at RBC. And we're pleased to have Spruce Biosciences with us today. Joining us is Javier Szwarcberg, CEO of Spruce Biosciences.
Just a reminder that if you have any questions for the team, we'll have a quick Q&A session in the end. And with that, Javier, thank you so much for joining us.
Javier Szwarcberg
Spruce Biosciences, Inc. - CEO
Sure, my pleasure to be here.
Questions & Answers
Yinglu Zhang
RBC Capital Markets - Analyst
Maybe just to get started, could you give us an introduction to the company and its lead asset, tildacerfont?
Javier Szwarcberg
Spruce Biosciences, Inc. - CEO
Sure. So Spruce was initially founded in 2014. We licensed tildacerfont from Eli Lilly with an asset that they had thought to develop for depression and anxiety and was repurposed for CAH. So in
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot